Achieving Bcl-2/IgH negativity in peripheral blood/bone marrow after therapy implies better prognosis for patients with follicular lymphoma
Authors:
D. Belada 1; L. Smolej 1; P. Štěpánková 1; M. Beránek 2; D. Dvořáková 3; J. Bukač 4; J. Malý 1
Authors‘ workplace:
Oddělení klinické hematologie II. interní kliniky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.
1; Ústav klinické biochemie a diagnostiky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Vladimír Palička, CSc.
2; Centrum molekulární biologie a genové terapie Interní hematoonkologické kliniky Lékařské fakulty MU a FN Brno, pracoviště Bohunice
přednosta prof. MUDr. Jiří Vorlíček, CSc.
3; Ústav lékařské biofyziky Lékařské fakulty UK Hradec Králové, přednosta doc. Ing. Josef Hanuš, CSc.
4
Published in:
Vnitř Lék 2007; 53(10): 1057-1063
Category:
Original Contributions
Overview
Bcl-2/IgH rearrangement is a characteristic molecular rearrangement in patients with follicular lymphoma (FL), yet its prognostic significance is still unclear.
Objective:
Evaluation of the implications of achieving Bcl-2/IgH negativity for the prognosis of FL patients. Twenty seven patients (54 %) were receiving only chemotherapy (CHT), 23 patients (46 %) were receiving chemotherapy combined with monoclonal antibody anti/CD20, rituximab (R-CHT).
Results:
Molecular genetic remission was achieved in 7 out of 11 patients (64 %) after R-CHT, and only in 2 out of 14 patients (14 %) after CHT – this difference was statistically significant (p = 0.037). 4 weekly doses of rituximab were administered in a sequence to 17 out of 27 patients who had received only chemotherapy and failed to achieve complete remission. 12 out of 17 patients (71 %) on this therapy were Bcl-2/IgH positive prior to treatment. 7 out of 12 (58 %) patients were no longer Bcl-2/IgH positive in a check performed after one month; the remaining 2 out of 5 patients had a negative Bcl-2/IgH record for the interval of 3 months (1 patient) or 6 (1 patient) months, respectively. The following factors were associated with the achievement of Bcl-2/IgH negativity at any point during the treatment: age < 65 years (p = 0.02) and performance status 0 + 1 according to WHO at baseline (p = 0.02). Patients who were Bcl-2/IgH negative after treatment had a lower recurrence/progression risk rate than the Bcl-2/IgH positive group of patients, i.e. 27 % vs. 75 % (p = 0.03), and a higher chance for progression-free survival, i.e. 81 % vs. 38 % (p = 0.004), event-free survival, i.e. 74 % vs. 38 % (p = 0.01), and overall survival, i.e. 87 % vs. 74 % (p = 0.05) at 2 years.
Conclusion:
In our experience, achieving Bcl-2/IgH negativity after follicular lymphoma therapy implies a better prognosis.
Keywords:
Bcl-2/IgH – follicular lymphoma 2 minimum residual disease – rituximab – prognosis
Sources
1. Apostolidis J, Gupta RK, Granzelias D et al. High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up. J Clin Oncol 2000; 18: 527-536.
2. Armitage J, Wiesenburger D New approach to classifying non-Hodgkin´s lymphomas. Clinical features of the major histologic subtypes. J Clin Oncol 1998; 16: 2780-2795.
3. Bakhshi A, Wright JJ, Graniger W et al. Mechanism of the t(14;18) chromosomal translocation: structural analysis of the both derivate 14 and 18 reciprocal partners. Proc Natl Acad Sci USA 1987; 84: 2396-2400.
4. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-106.
5. Czuczman MS, Grillo-López AJ, McLauglin P, White CA et at. Clearing of celles bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 2001; 12: 109-114.
6. Foran JM, Gupta RK, Cunningmam D et al. A UK multicentre phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Heamatol 2000; 109: 81-88.
7. Glass AG, Karnell LH, Menck HR. The national Cancer Data Base report on non-Hodgkin’s lymphoma. Cancer 1997; 80: 2311-2320.
8. Gribben JG, Freedman AS et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Eng J Med 1991; 325: 1525-1531.
9. Gribben JG, Neuberg D, Barber M et al. Detection of Residual Lymphoma Cells by Polymerase Chain Reaction in Peripheral Blood Is Significantly Less Predictive for Relapse Than Detection in Bone Marrow. Blood 1994; 83: 3800-3807.
10. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non‑Hodgkin’s lymphomas. J Clin Oncol 1999; 17: 1244. Erratum in: J Clin Oncol 2000; 18: 2351.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
12. Ladetto M, Corradini P, Vallet S et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Middolo Osseo (GIMTO). Blood 2002; 100: 1559-1564.
13. Lopez-Guillermo A, Cabanillas F, McLauglin P et al. Molecular response assessed by PCR is the most important factor predicting failure-gree survival in indolent follicular lymphoma: Update of the MDACC series. Ann Oncol 2000; 11(Suppl 1): S137-S140.
14. Mahé B, Milpied N, Mellerin MP et al. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin’s lymphoma. Bone Marrow Transpl 2003; 31: 467-473.
15. Mandigers CM, Meijerink PP, Mensink EM et al. Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood 2001; 98: 940-944.
16. Papajík T, Jedličková K, Krigerová E et al. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long term follow-up. Neoplasma 2001; 6: 501-505.
17. Pezzela F, Jones M, Ersboll J et al. Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. British J Can 1992; 65: 87-89.
18. Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856-862.
19. Reff ME, Carner K et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
20. Rogers J, Jackson J, Rosenberg J et al. Clearance of bcl-2 t(14;18) from peripheral blood and bone marrow in patients with relapsed low-grade or follicular lymphoma following single-agent therapy with the chimaeric anti-CD20 antibody IDEC-C2B8. Ann Oncol 1996; 7: 108a (abstract).
21. Summers KE, Davies AJ, Matthews J et al. The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerace Chin reaction. Br J Haematol 2002; 118: 563-566.
22. Tsijumoto Y, Finger L, Yunis J et al. Cloning of the chromosome braekpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097-1099.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2007 Issue 10
Most read in this issue
- Cortisol levels are more closely associated with depressiveness and other psychopathologies than catecholamine levels
- Pseudomembranous colitis
- Pulmonary alveolar proteinosis
- Our experience in continuous administration of insulin using infusion dispenser at a metabolic intensive care unit (MICU)